NuCana (NCNA) trims losses in H1 2026 and sees cash runway into 2029
Rhea-AI Filing Summary
NuCana plc reported substantially lower losses for the quarter and six months ended June 30, 2026 while remaining a pre-revenue, clinical-stage oncology company. For the quarter, the net loss was £3.1 million versus £24.1 million a year earlier, largely reflecting the absence of a prior-year £12.6 million non-cash warrant revaluation loss and sharply reduced research and development and administrative expenses. For the first half, the net loss was £6.9 million compared with £26.6 million in 2025.
Cash and cash equivalents were £19.5 million at June 30, 2026, down from £24.3 million at year-end 2025. Management expects this to fund planned operations into 2029 and continues to use an at-the-market program, raising £0.2 million in the first half and a further £0.3 million after period end. The pipeline is led by NUC-7738, now fully recruited in a Phase 2 expansion study in PD‑1 inhibitor‑resistant metastatic melanoma following FDA IND clearance, and by NUC‑3373, for which further development strategy is being evaluated. Accumulated deficit reached £253.7 million, and the company reiterates it expects ongoing losses until successful commercialization.
Positive
- Net loss significantly reduced: quarterly loss fell to £3.1 million from £24.1 million, and six‑month loss to £6.9 million from £26.6 million, aided by lower R&D/admin costs and no repeat of a £12.6 million non‑cash warrant revaluation.
- Extended cash runway: cash of £19.5 million at June 30, 2026 is expected to fund planned operations into 2029, supported by an active ATM equity program.
- Key clinical milestone: recruitment is complete in the Phase 2 NuTide:701 expansion study of NUC‑7738 plus pembrolizumab in PD‑1 inhibitor‑resistant metastatic melanoma, with final data expected in 2026 and ongoing FDA dialogue on a potential registrational path.
Negative
- Ongoing losses and deficit: the company remains pre‑revenue, posted a £6.9 million loss in the first half of 2026, and has an accumulated deficit of £253.7 million, with profitability dependent on successful development and commercialization of its product candidates.
- Reliance on future financing: management states it will need additional capital beyond the going‑concern assessment period and may also require more funds if it expands development programs, with no assurance such financing will be available on acceptable terms.
Filing Explained
After June 30, NuCana sold and issued 275,712 ADSs for £0.3 million through the ATM; the shelf provides capacity, not an additional completed sale.
Form 6-K is a foreign private issuer’s interim report; NuCana furnishes second-quarter statements, management discussion and a press release, and incorporates specified exhibits into its F-3 and S-8 registration statements.
After
Issuing additional shares increases the share count and reduces existing holders’ percentage ownership absent offsetting changes.
On
At
The ATM arrangement allows periodic sales with an aggregate offering price of up to
Those figures describe maximum capacity; the filing separately records the completed post-period issuance and proceeds above.
The next specified development milestone is final data from the Phase 2 NUC-7738 expansion study, which the company says remains on track for later in 2026.
Key Figures
Key Terms
ProTide technology medical
thymidylate synthase medical
Investigational New Drug application regulatory
at-the-market program financial
research and development tax credits financial
Phase 2 expansion study medical
FAQ
How did NuCana (NCNA) perform financially in Q2 2026?
What is NuCana’s (NCNA) cash position and runway as of June 30, 2026?
How much did NuCana (NCNA) spend on R&D in H1 2026 versus H1 2025?
What are the key clinical updates for NuCana’s (NCNA) NUC-7738 program?
How is NuCana (NCNA) using its ATM program for financing?
AI-generated analysis. How Rhea-AI works. Not financial advice.
